Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 6Autoimmune Diseases 3Neuromuscular Diseases 1Muscle Weakness 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Data Collection 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Blood Specimen Collection 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1human papillomavirus vaccine, L1 type 16, 18 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1apremilast 1Watchful Waiting 1Vitamin D 1Valsartan 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Pyridostigmine Bromide 1Practice Guidelines as Topic 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Phlebotomy 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Autoimmune Diseases × telitacicept × Clear all
NCT05737160 2025-05-23

Study of Telitacicept in Generalized Myasthenia Gravis

RemeGen Co., Ltd.

Phase 3 Completed
114 enrolled

Autoimmune Diseases, Myasthenia Gravis, Muscle Weakness

NCT06827587 2025-02-14

Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase NA Not yet recruiting
60 enrolled

Autoimmune Diseases, Myasthenia Gravis, Neuromuscular Diseases

NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡